Liquisolid pharmaceutical formulation for treating hypertension comprises hesperidin, a solvent, a carrier, a coating material, polyvinylpyrrolidone K30, crospovidone, and, magnesium stearate, where the hesperidin is dispersed in solvent to form a liquid medication and loaded onto the carrier
	KAUR S D; KAPOOR D; SHARMA P
	2023-07-27
专利权人	UNIV SHOOLINI BIOTECHNOLOGY & MANAGEMENT (USLN-C)
申请日期	2023-07-27
专利号	IN202311050592-A
成果简介	NOVELTY - Liquisolid pharmaceutical formulation comprises hesperidin, a solvent, a carrier, a coating material, polyvinylpyrrolidone (PVP) K30, crospovidone, and, magnesium stearate, where the hesperidin is dispersed in the solvent to form a liquid medication and loaded onto the carrier, and the coating material, forming a liquisolid system; where the solvent is polyethylene glycol 400 (PEG 400); the carrier is microcrystalline cellulose; the coating material is silicon dioxide; and where the liquisolid pharmaceutical tablet exhibit a percentage of drug release of 55-72 % in a phosphate buffer. USE - Liquisolid pharmaceutical formulation for treating inflammatory conditions, allergies, cardiovascular diseases, hypertension, diabetes, tumors, and ulcers. ADVANTAGE - The formulation has high solubility, bioavailability, and dissolution rate, is environmentally friendly, does not contain any hazardous or harmful chemicals, suitable for industrial production. The process is cost-effective, simple. The Pharmacokinetic property of formulation was tested in rats using in-vivo. The result showed that (I) exhibited Cmax value of 387.43 µg/mL. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a process of preparing a liquisolid pharmaceutical formulation which involves (a) dissolving hesperidin in PEG 400 at a ratio of 1:2 to prepare a drug solution; (b) adding the drug solution to 394.7 mg microcrystalline cellulose while continuously mixing in a mortar; (c) adding and mixing 39.47 mg silicon dioxide to the mixture to convert it to a dry powdered blend; (d) passing the dry powdered blend through a sieve to provide uniform particle size; (e) adding 5-40 mg crospovidone to the blend and further mixing for 10 minutes; (f) adding 5-50 mg PVP K30 (binder): to the blend and further mixing for 2 minutes; (g) adding 5.84 mg of Magnesium Stearate to the blend and further mixing for 5 minutes; (h) compressing the blend into tablets using a compression machine to form the liquisolid pharmaceutical tablet.
IPC 分类号	A61K-031/7048 ; A61K-009/16
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/21089
专题	中国科学院新疆生态与地理研究所
作者单位	UNIV SHOOLINI BIOTECHNOLOGY & MANAGEMENT (USLN-C)
推荐引用方式 GB/T 7714	KAUR S D,KAPOOR D,SHARMA P. Liquisolid pharmaceutical formulation for treating hypertension comprises hesperidin, a solvent, a carrier, a coating material, polyvinylpyrrolidone K30, crospovidone, and, magnesium stearate, where the hesperidin is dispersed in solvent to form a liquid medication and loaded onto the carrier. IN202311050592-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。